Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by palinc2000on Jul 25, 2022 12:59pm
153 Views
Post# 34848579

RE:RE:I spoke with LaFond this morning

RE:RE:I spoke with LaFond this morningChina deal in the near future ,,,???,?We heard from another poster that Lafond does not understand oncology and yet he has to be involved in the legal documentation related to a China deal....
My faith in a soon to be China deal has almost completely vanished ...Why would Lafond sell if they were in the midst of negotiations for a cash injection by a Chinese bio? Its either no deal or if there is a deal coming  Lafond is .......I cant find the proper adjective!!!




Wino115 wrote: So, instead of pushing management to do something constructive around building an audience for the share that provides both proper valuation and sufficient liquidity, he says nothing about this major issue and bails.  That is the kind of internal pressure a shareholder would want to see on the management team. And he frets for it over the next 5 months.

If these were granted back in the 2016 timeframe, he's been compensated plenty over the hears to pay for that tax hit out of pocket. That's 6 years of pretty decent, growing pay, with bonuses at max.  And I could be wrong, but the tax bill would be around $20k --or to look at it another way $3k a year he could have saved up. I don't mean to dimish a $20k tax liability but the simple fact is that for the last 3 years he could easily see that there would be a decent tax bill due on those and could have started to "defease" the bill knowing he would want to keep the shares for a company in which he loves the fact they take risks and have potential big payouts for.  Selling after being within months of significant news is a no-no.

Lastly, if you actually thought there'd be good news coming, not only would you have a sweet bonus to either pay that tax off or nicely rebuild that savings pot beyond where it was, PLUS, you'd have paid up shares that could literally be worth 10x that tax bill then you would not have sold them.  He is showing zero faith in milestones changing the trajectory of the company valuation or the liquidity.  Time to look for a new in-house counsel who gets it and understands the severe value destruction company shareholders have witnessed over the last 3 years of a bull market. 

SPCEO1 wrote: Our new head of IR kindly put together a quick call with Jocelyn, which was appreciated given the negative impact of this news. 

He noted the trading volume is low so maybe he did not want to be in a position where he exercised them on the last day and then sold into a low volume market?




<< Previous
Bullboard Posts
Next >>